1. Home
  2. NPWR vs ADCT Comparison

NPWR vs ADCT Comparison

Compare NPWR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NET Power Inc.

NPWR

NET Power Inc.

HOLD

Current Price

$1.81

Market Cap

137.0M

Sector

Energy

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.07

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPWR
ADCT
Founded
2010
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
137.0M
136.1M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
NPWR
ADCT
Price
$1.81
$1.07
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$3.50
$7.75
AVG Volume (30 Days)
899.0K
1.8M
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
N/A
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$1.35
$0.78
52 Week High
$5.20
$4.98

Technical Indicators

Market Signals
Indicator
NPWR
ADCT
Relative Strength Index (RSI) 51.58 46.02
Support Level $1.65 $0.98
Resistance Level $1.84 $1.20
Average True Range (ATR) 0.12 0.09
MACD -0.01 -0.00
Stochastic Oscillator 26.40 36.59

Price Performance

Historical Comparison
NPWR
ADCT

About NPWR NET Power Inc.

NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. Its business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. The company has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: